The FDA has cleared of the measurement of respiration rate from the pleth (RRp) on the Masimo MightySat Rx spot-check fingertip pulse oximeter, as well as its indication for use in the home environment.
The addition of RRp to MightySat Rx, which also measures functional oxygen saturation (SpO2), pulse rate (PR), perfusion index (Pi), and Pleth Variability Index (PVi), makes it a more thorough and versatile spot-check solution.
Respiration rate typically requires manually counting breaths with a timer and then converting to a rate per minute, or being fitted with chest leads or straps that can be inconvenient. With RRp, respiration rate can conveniently be measured using the same optical sensor that measures SpO2, PR, Pi, and PVi.
RRp is provided only when the respiratory movement-induced signal is present in the pulsatile waveform and may not be available during certain conditions, such as very irregular breathing and excessive movement.
With the introduction of RRp to the US, Masimo now offers clinicians more ways to accurately measure breathing rate than ever, helping to ensure they have the right tools for each patient scenario. RRp on MightySat Rx offers a convenient, fast, and portable option, adding to the portfolio of respiratory solutions from Masimo that includes continuous, acoustic respiration rate monitoring using RRa and capnography-based solutions using NomoLine.
More information on the MightySat Rx is available at Masimo’s website.